5004202025-01-012025-03-315004202025-03-315004202024-03-315004202024-04-012025-03-315004202025-01-012025-03-31in-capmkt:OtherExpenses1Member5004202024-04-012025-03-31in-capmkt:OtherExpenses1Member5004202025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15004202024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15004202025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15004202024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15004202025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares500420TORNTPHARMNOTLISTEDINE685A01028TORRENT PHARMACEUTICALS LIMITEDMain BoardEquity2024-04-012025-03-312025-05-202025-05-13INRCroresQuarterlyFourth quarterSingle segmentGeneric Formulation Business2025-05-2014:20:002025-05-2016:30:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated29590000000-1800000002941000000040200000004160000000-870000000561000000056000000020100000007030000000225200000006890000000-24000000066500000001840000000-17000000016700000000498000000000004980000000360000000534000000049800000000534000000001692300000514.7114.710014.7114.710.0040.04910.13661. Exceptional item for the quarter and year ended March 31, 2025, relates to a demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017 concerning alleged overcharging, which was under judicial consideration before the Hon’ble Gujarat High Court. During the year, the parent company submitted detailed representations, which were favourably considered by the NPPA. As a result, the parent company’s legal exposure was substantially reduced. Following the issuance of a revised demand by the NPPA, the parent company opted to settle the litigation and bring the matter to a definitive close. <BR> <BR> 2. The Income Tax Act, 1961, provides an option to the parent company for paying tax at reduced rates (lower tax rate) as per the provisions/conditions defined in the Income Tax Act, 1961 (Section 115BAA).With reference to the same, the parent company had previously assessed the option of availing the lower tax rate under Section 115BAA, in future years, and accordingly applied a mixed tax rate of 25.17% for deferred tax items expected to reverse after transitioning into new regime and 34.94% for those expected to reverse before the transition. Based on the current-year evaluation of available MAT credits and deductions under Chapter VIA as at March 31, 2025, the parent company has now assessed that it will transition to the new tax regime from FY 2025-26. Consequently, deferred tax balances expected to reverse in or after FY 2025-26 have been remeasured at 25.17%, resulting in a net reversal of deferred tax liabilities of Rs. 151 crores for the year ended March 31, 2025.2024-04-012025-03-31AuditedConsolidated1151600000002300000001153900000001520000000015310000000-27500000002203000000025200000007950000000281600000008842000000026970000000-24000000026730000000619000000014300000007620000000019110000000000019110000000-93000000018180000000191100000000181800000000169230000057422000000056.4756.470056.4756.470.0040.03870.1243Other Expenses7030000000Other Expenses2816000000034550000000367000000003390000000415200000001110000000004400000000300000003300000008000000005950000000268000000093670000000254100000001120000000186700000005730000000600000005000000018300000002746000000003360000000562300000000014990000000016900000007422000000075910000000075910000000119200000000001600000000135200000005010000000829000000000268200000001834000000023000000017970000000182000000004230000000407700000001360000000408000000096000000004717000000000739900000001499000000002520000000-26200000001700000000-5200000000000-278000000009400000000795000000000000-1500000000200000000000-1800000002000000000515000000031880000000000603000000002585000000000450000000000010000000018000000061100000000000000000000000002000000000-20000000-5400000000000000000926000000027000000010830000000262000000000-22980000000-2530000000-90000000-262000000083500000005730000000Amount of items that will not be reclassified to profit and loss-90000000-90000000Amount of items that will not be reclassified to profit and loss-280000000-28000000010000000-60000000Amount of items that will be reclassified to profit and loss520000000520000000Amount of items that will be reclassified to profit and loss-780000000-78000000060000000-70000000360000000-930000000AuditedtrueBSR & Co. LLPtrue2025-07-31